Circulating tumor cell technology is an enabling technology for recovery and analysis of separated cancer cells in the peripheral blood. CTC technology offers advantages like high sensitivity, high specificity, reproducible, repeatable, and non-invasive diagnostic assay for guiding treatment decision and improved patient triage. Circulatory tumor cells (CTC) are cancer cells that get separated from the primary tumor or its metastases that circulate in the peripheral blood. Metastasis the major cause of cancer deaths and CTC may constitute seeds from metastases and indicate the spread of diseases. The circulating tumor cells' analysis will allow early detection of metastasis when it is less invasive. Molecular characterization of CTC enables the treatment to be planned effectively. Removing CTC from the blood will limit metastases after surgery or therapy.
Molecular characterization is significant from the point of view of developing new methodologies for CTC detection, isolation, enumeration, and subsequent genetic or proteomic analysis. Advancement in medical technologies is allowing efficient removal of CTC from circulation and has therapeutic potential.
This research report analyzes the Circulating tumor cells and cancer stem cells market from a technical as well as business perspective, describing the overall market size, industry growth rate, and market trends. It gives an analysis of the recent developments in CTC and CSC markets and includes detailed profiles of top industry players along with Porter's five force analysis. The report also analyzes all the micro and macro factors essential for the existing market players and new entrants along.
Major regions covered under this research study are North America, Europe, the Asia-Pacific, and the Rest of the World.
Browse more Biomarker Market Research Reports